HRP20191339T1 - Novi anelirani fenoksiacetamidi - Google Patents
Novi anelirani fenoksiacetamidi Download PDFInfo
- Publication number
- HRP20191339T1 HRP20191339T1 HRP20191339TT HRP20191339T HRP20191339T1 HR P20191339 T1 HRP20191339 T1 HR P20191339T1 HR P20191339T T HRP20191339T T HR P20191339TT HR P20191339 T HRP20191339 T HR P20191339T HR P20191339 T1 HRP20191339 T1 HR P20191339T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- accordance
- inhibitors
- Prior art date
Links
- AOPRXJXHLWYPQR-UHFFFAOYSA-N 2-phenoxyacetamide Chemical class NC(=O)COC1=CC=CC=C1 AOPRXJXHLWYPQR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 23
- -1 4-tetrahydropyranylmethyl Chemical group 0.000 claims 7
- 206010006451 bronchitis Diseases 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010001889 Alveolitis Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000006224 2-tetrahydrofuranylmethyl group Chemical group [H]C([H])(*)C1([H])OC([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010052613 Allergic bronchitis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000006968 Helminthiasis Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000003454 betamimetic effect Effects 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (24)
1. Spoj, naznačen time, da je predstavljen formulom (I),
u kojoj
R1 i R2 su neovisno odabrani od etila, 2-hidroksietila, 2tetrahidrofuranilmetila i 4-tetrahidropiranilmetila;
R3 je odabran od dijela skupine NRaRb, pri čemu su Ra i Rb neovisno odabrani od vodika, C1-C4-alkila i 1-(2-etoksietil)piperidin-4-ila, gdje C1-C4-alkil može nositi 1 ili 2 supstituenta odabrana od hidroksila, amino, C1-C4-alkilamino, di-C1-C4-alkilamino, (dimetilfosfinoil)metoksi, 4-(dimetilfosfinoil)fenila, 6-metil-3-hidroksi-piridin-2-ila i oksianiona od 6-metil-3-hidroksi-piridin-2-ila, uz uvjet da je najmanje jedan od Ra i Rb različit od vodika,
ili pri čemu Ra i Rb zajedno s dušikom na kojega su priključeni, tvore heterociklički dio skupine odabrane od piperidina i 1oksotiomorfolinila, gdje heterociklički dio skupine može nositi 1 ili 2 supstituenta odabrana od NH2; i
Z-je odabran od klorida, bromida, jodida, hidroksida, vodikovog sulfata, sulfata, nitrata, fosfata, formata, acetata, trifluoroacetata, fumarata, citrata, tartrata, oksalata, sukcinata, mandelata, metansulfonata i ptoluensulfonata,
ili Z- može biti odsutan ako Ra ili Rb je C1-C4-alkil i nosi oksianion od
6metil-3-hidroksi-piridin-2-ila;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj u skladu sa zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da najmanje jedan od R1 i R2 je etil.
3. Spoj u skladu sa zahtjevom 2 ili njegova farmaceutski prihvatljiva sol, naznačen time, da oba dva R1 i R2 su etil.
4. Spoj u skladu s bilo kojim od zahtjeva 1 do 3 ili njegova farmaceutski prihvatljiva sol, naznačen time, da Z- je odabran od klorida, formata, i trifluoroacetata.
5. Spoj u skladu s bilo kojim od zahtjeva 1 do 4 ili njegova farmaceutski prihvatljiva sol, naznačen time, da R3 je odabran od sljedećih:
6. Spoj u skladu sa zahtjevom 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da je odabran iz skupine koja se sastoji od sljedećih:
7. Spoj u skladu s bilo kojim od zahtjeva 1 do 6, naznačen time, da je
8. Postupak sintetiziranja farmaceutski prihvatljive soli od spojeva u skladu sa zahtjevom 7, naznačen time, da izvorni spoj koji sadrži kationsku skupinu, reagira putem konvencionalnih kemijskih postupaka.
9. Postupak sintetiziranja farmaceutski prihvatljive soli od spojeva u skladu sa zahtjevom 8, naznačen time, da izvorni spoj koji sadrži kationsku skupinu, reagira s dovoljnom količinom prikladne baze ili kiseline u vodi ili u organskom razrjeđivaču.
10. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (1.02) u skladu sa zahtjevom 7.
11. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (2.03) u skladu sa zahtjevom 7.
12. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (2.04) u skladu sa zahtjevom 7.
13. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (2.05) u skladu sa zahtjevom 7.
14. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (2.06) u skladu sa zahtjevom 7.
15. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (1.03) u skladu sa zahtjevom 7.
16. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (1.1) u skladu sa zahtjevom 7.
17. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (2.01) u skladu sa zahtjevom 7.
18. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (2.07) u skladu sa zahtjevom 7.
19. Farmaceutski prihvatljiva sol, naznačena time, da je ona od izvornog spoja za spoj (2.02) u skladu sa zahtjevom 7.
20. Spoj u skladu s jednim ili više od zahtjeva 1 do 19 ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava kao lijek.
21. Spoj u skladu s jednim ili više od zahtjeva 1 do 19 ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u liječenju bolesti odabrane između respiratornih bolesti ili poremećaja i alergijskih bolesti dišnih puteva.
22. Spoj u skladu s jednim ili više od zahtjeva 1 do 19 ili njegova farmaceutski prihvatljiva sol, naznačen time, da se upotrebljava u liječenju bolesti odabrane između kroničnog bronhitisa, akutnog bronhitisa, bronhitisa prouzročenog bakterijskom ili virusnom infekcijom ili gljivično ili infekcijom helmintima, alergijski bronhitis, toksični bronhitis, kronični opstrukcijski bronhitis (COPD), astma, dječja astma, bronhiektaza, alergijski alveolitis, alergijski ili nealergijski rinitis, kronični sinusitis, idiopatska plućna fibroza, cistična fibroza ili mukoviscidoza, deficijencija alfa-1-antitripsina, kašalj, plućni emfizem, intersticijske plućne bolesti, alveolitis, hiperreaktivni dišni putevi, nosni polipi, plućni edem, pneumonitis različitog podrijetla, i suhe oči.
23. Farmaceutski pripravak, naznačen time, da obuhvaća najmanje jedan spoj u skladu s jednim ili više od zahtjeva 1 do 19 ili njegovu farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač.
24. Lijekovita kombinacija, naznačena time, da ona sadrži, osim jednog ili više spojeva u skladu s jednim ili više od zahtjeva 1 do 19 ili njegove farmaceutski prihvatljive soli, kao dodatne djelatne tvari, jedan ili više spojeva odabranih između kategorija dodatnih ENaC-inhibitora, betamimetika, antikolinergika, kortikosteroida, PDE4-inhibitora, LTD4-antagonista, EGFR-inhibitora, agonista dopamina, H1-antihistamina, PAF-antagonista, inhibitora MAP-kinaze, MPR4-inhibitora, iNOS-inhibitora, SYK-inhibitora, korekcijska sredstva za transmembranski regulator cistične fibroze (CFTR) i CFTR potencijacijska sredstva ili njihove dvostruke ili trostruke kombinacije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/069152 WO2017028927A1 (en) | 2015-08-20 | 2015-08-20 | Novel annelated phenoxyacetamides |
| EP15760394.5A EP3298022B1 (en) | 2015-08-20 | 2015-08-20 | Novel annelated phenoxyacetamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191339T1 true HRP20191339T1 (hr) | 2020-02-21 |
Family
ID=54065852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191339TT HRP20191339T1 (hr) | 2015-08-20 | 2019-07-24 | Novi anelirani fenoksiacetamidi |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP3298022B1 (hr) |
| JP (1) | JP6620171B2 (hr) |
| KR (1) | KR20180044333A (hr) |
| CN (1) | CN108200769B (hr) |
| AU (1) | AU2015406100B2 (hr) |
| BR (1) | BR112018001035A2 (hr) |
| CA (1) | CA2996087A1 (hr) |
| CO (1) | CO2018001700A2 (hr) |
| CY (1) | CY1122077T1 (hr) |
| DK (1) | DK3298022T3 (hr) |
| EA (1) | EA035738B1 (hr) |
| ES (1) | ES2739893T3 (hr) |
| HR (1) | HRP20191339T1 (hr) |
| HU (1) | HUE046014T2 (hr) |
| IL (1) | IL257136B (hr) |
| LT (1) | LT3298022T (hr) |
| ME (1) | ME03534B (hr) |
| MX (1) | MX370598B (hr) |
| MY (1) | MY194711A (hr) |
| PH (1) | PH12018500378B1 (hr) |
| PL (1) | PL3298022T3 (hr) |
| PT (1) | PT3298022T (hr) |
| RS (1) | RS59169B1 (hr) |
| SA (1) | SA518390920B1 (hr) |
| SI (1) | SI3298022T1 (hr) |
| UA (1) | UA121414C2 (hr) |
| WO (1) | WO2017028927A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| CN116438200A (zh) | 2020-09-10 | 2023-07-14 | 普雷西里克斯公司 | 针对fap的抗体片段 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011079087A1 (en) * | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
| JP6461134B2 (ja) * | 2013-07-15 | 2019-01-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ベンゾイミダゾリウム化合物 |
| JP6461948B2 (ja) * | 2013-07-15 | 2019-01-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規５−置換ベンゾイミダゾリウム化合物 |
| WO2015007517A1 (en) * | 2013-07-15 | 2015-01-22 | Boehringer Ingelheim International Gmbh | Novel tetra- and pentasubstituted benzimidazolium compounds |
-
2015
- 2015-08-20 MX MX2018001945A patent/MX370598B/es active IP Right Grant
- 2015-08-20 WO PCT/EP2015/069152 patent/WO2017028927A1/en active Application Filing
- 2015-08-20 PT PT15760394T patent/PT3298022T/pt unknown
- 2015-08-20 DK DK15760394.5T patent/DK3298022T3/da active
- 2015-08-20 ES ES15760394T patent/ES2739893T3/es active Active
- 2015-08-20 LT LTEP15760394.5T patent/LT3298022T/lt unknown
- 2015-08-20 EA EA201890534A patent/EA035738B1/ru not_active IP Right Cessation
- 2015-08-20 SI SI201530828T patent/SI3298022T1/sl unknown
- 2015-08-20 RS RSP20191100 patent/RS59169B1/sr unknown
- 2015-08-20 CN CN201580083568.7A patent/CN108200769B/zh active Active
- 2015-08-20 KR KR1020187007950A patent/KR20180044333A/ko unknown
- 2015-08-20 UA UAA201802620A patent/UA121414C2/uk unknown
- 2015-08-20 CA CA2996087A patent/CA2996087A1/en not_active Abandoned
- 2015-08-20 HU HUE15760394A patent/HUE046014T2/hu unknown
- 2015-08-20 BR BR112018001035-9A patent/BR112018001035A2/pt active Search and Examination
- 2015-08-20 EP EP15760394.5A patent/EP3298022B1/en active Active
- 2015-08-20 PL PL15760394T patent/PL3298022T3/pl unknown
- 2015-08-20 JP JP2017564088A patent/JP6620171B2/ja active Active
- 2015-08-20 MY MYPI2018000198A patent/MY194711A/en unknown
- 2015-08-20 ME MEP-2019-247A patent/ME03534B/me unknown
- 2015-08-20 AU AU2015406100A patent/AU2015406100B2/en not_active Ceased
-
2018
- 2018-01-24 IL IL257136A patent/IL257136B/en unknown
- 2018-02-13 SA SA518390920A patent/SA518390920B1/ar unknown
- 2018-02-20 PH PH12018500378A patent/PH12018500378B1/en unknown
- 2018-02-20 CO CONC2018/0001700A patent/CO2018001700A2/es unknown
-
2019
- 2019-07-24 HR HRP20191339TT patent/HRP20191339T1/hr unknown
- 2019-09-05 CY CY20191100932T patent/CY1122077T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191339T1 (hr) | Novi anelirani fenoksiacetamidi | |
| HRP20171614T1 (hr) | Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju | |
| JP2016534088A5 (hr) | ||
| JP2018529657A5 (hr) | ||
| ES2292988T3 (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| JP2016532677A5 (hr) | ||
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| MY154895A (en) | Pyrimidine hydrazide compounds as pgds inhibitors | |
| MX2009000999A (es) | Derivados de quinuclidina como antagonistas de m3. | |
| JP2014534222A5 (hr) | ||
| PT1252157E (pt) | Carboxamidas de pirimidina uteis como inibidores de isozimas pde4 | |
| TW200616967A (en) | Novel indazole carboxamides and their use | |
| NO20051540L (no) | 2,5-dioksoimidazolidin-4-yl acetamider og analoger som inhibitorer av metalloproteinas MMP12 | |
| TW200708513A (en) | Novel crystalline forms of tiotropium bromide | |
| ECSP14013173A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida | |
| CY1114804T1 (el) | Νεες ενωσεις 951: ενα διφαινυλοξυπροπανοϊκο οξυ ως ρυθμιστης crth2 και ενδιαμεσες ενωσεις | |
| JP2011509284A5 (hr) | ||
| PE20070081A1 (es) | Derivados de 2,6-quinolinilo y preparaciones que los comprenden | |
| PE20081779A1 (es) | Derivados de nicotinamida | |
| MX2009010270A (es) | Indol carboxamidas como inhibidores de quinasas ikappa2. | |
| AR078552A1 (es) | Derivados de feniloxadiazol como agentes inhibidores de las pgds | |
| HRP20120869T1 (hr) | Spirocikliäśki heterocikli, lijekovi koji sadrže te spojeve, njihova uporaba te postupak njihove proizvodnje | |
| TW200307545A (en) | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases | |
| NO20080457L (no) | Kjemiske forbindelser | |
| NO20081480L (no) | Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma |